Meeting
2022 ASCO Annual Meeting
Next-generation sequencing (NGS) for identifying actionable molecular alterations in patients with newly diagnosed and recurrent IDHwt-glioblastoma (GBM): A large mono-institutional experience.
Authors
Marta Padovan
Department of Oncology, Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy
Marta Padovan , Marta Maccari , Alberto Bosio , Salvatore Vizzaccaro , Ilaria Cestonaro , Martina Corrà , Mario Caccese , Giulia Cerretti , Matteo Fassan , Vittorina Zagonel , Giuseppe Lombardi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Tissue-Based Biomarkers
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 3139)
DOI
10.1200/JCO.2022.40.16_suppl.3139
Abstract #
3139
Poster Bd #
131
Abstract Disclosures
Similar Posters
Poster
2019 Gastrointestinal Cancers Symposium
Genomic alterations in appendiceal carcinoma using circulating DNA.
First Author: Walid Labib Shaib
Poster
2022 ASCO Annual Meeting
Clinical implications of tumor-based next-generation sequencing in ovarian cancer.
First Author: Katherine Foster
Poster
2022 ASCO Annual Meeting
Clinicopathologic characterization of ERK2 E322K mutation in solid tumors: Implications for treatment and drug development.
First Author: Dazhi Liu
Poster
2021 ASCO Annual Meeting
Malignant glioma subset from Actuate 1801: A phase 1/2 study of 9-ING-41, a glycogen synthase kinase 3 beta (GSK-3β) inhibitor, as a single agent and combined with chemotherapy, in patients with refractory hematologic malignancies or solid tumors.
First Author: Yazmin Odia